April 10, 2025 10:46 AM EDT
R&D

J&J, ar­genx keep rolling out myas­the­nia gravis da­ta, plus more from #AAN25

Max Gelman

Senior Editor

Last week­end, re­searchers gath­ered in San Diego for the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing to dis­cuss the lat­est ad­vance­ments and clin­i­cal tri­al da­ta across …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

A service from the Financial Times